C09951: Hybridoma Cell Line Secreting Mouse CD19 AntibodyNovelty:
Hybridoma cell line (1D3) secreting the monoclonal antibody against the murine homologue of B-cell CD19 protein.
Value Proposition:
CD19 is a B lymphocyte-lineage antigen and has been associated with cancer progression, notably B-cell lymphomas. Therefore, extensive animal model study can help discover new drugs and therapies in this field. This invention is a monoclonal antibody that is specific to the CD19 protein in mouse B-cells.
• Promise of CD19 as drug target can be tested
• Drug screening and validation
• Study the implication of CD19 in cancers
Technical Details:
Johns Hopkins researchers have established the 1D3 hybridoma producing murine anti-CD19 antibody. CD-19 is a surface molecule for B-cell antigen receptors and participates in B-lymphocyte development, activation, maturation of memory B cells and regulation of tolerance. Thus the antibody is a very useful tool in immunohistochemistry and flow cytometry studies of B-cells in mouse models.
Looking for Partners:
To license the technology for internal research use.
Stage of Development:
Ready for use
Data Availability:
Under CDA / NDA
Publications/Associated Cases:
Not available at this time
